“At a business level the deal made great strategic sense,” said Cooley Godward partner Keith Flaum, who represented South San Francisco-based Cor in the merger. Millennium is a research and development “machine that’s great at finding products and developing relationships” while Cor has a cardiovascular product on the market.
Millennium, based in Cambridge, Mass., has focused in the areas of oncology, inflammation and metabolic disease. The company markets two products, Campath, for the treatment of B-cell chronic lymphocytic leukemia, and Melastatin, a diagnostic for determining the risk of skin cancer.
